ORRxD combines computation with experiment to bring hit compounds through the process of hit-to-lead discovery, structure-based lead optimization for affinity and selectivity, metabolic stability, bioavailability and animal model testing up to investigational new drug status. ORRxD has drug candidates in various stages of development for Osteoporosis, Ricketts, Chronic Kidney Disease, Hypophosphatemia, Diabetes, Prostate Cancer, and Polycystic Kidney Disease.
​
Current Pipeline includes list below:
Medical Condition
Target
Results
Current
Work
Hypophosphatemia,
CKD,
FGF23/Klotho
Identified and optimized lead compounds with in vitro and in vivo efficacy
ADME, Toxicity, PK studies
Prostate Cancer
GPCRC6A (antagonists)
Leads discovered and validated in vitro and in vivo.
Lead optimization
Type 2 Diabetes,
NAFLD
GPCRC6A (agonists)
Leads discovered and validated in vitro and in vivo.
Lead optimization
Senile Osteoporosis
PC1/PC2/TAZ;
Leads discovered and validated in vitro and in vivo.
Lead optimization
ADME, Toxicity, PK studies
Inflammation,
Obesity,
Cancer,
Castleman Disease
IL-6
Multiple hits discovered and validated in vitro.
Additional validation and hit expansion